119 related articles for article (PubMed ID: 22815188)
1. Preoperative serum tissue polypeptide-specific antigen is a valuable prognostic marker in breast cancer.
Ahn SK; Moon HG; Ko E; Kim HS; Shin HC; Kim J; You JM; Han W; Noh DY
Int J Cancer; 2013 Feb; 132(4):875-81. PubMed ID: 22815188
[TBL] [Abstract][Full Text] [Related]
2. Serum tissue polypeptide-specific antigen is an independent predictor in breast cancer.
Xie S; Ding X; Mo W; Chen J
Acta Histochem; 2014 Mar; 116(2):372-6. PubMed ID: 24144486
[TBL] [Abstract][Full Text] [Related]
3. [Clinical and prognostic significance of preoperative serum CA153, CEA and TPS levels in patients with primary breast cancer].
Chen Y; Zheng YH; Lin YY; Hu MH; Chen YS
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):842-6. PubMed ID: 22335950
[TBL] [Abstract][Full Text] [Related]
4. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
[TBL] [Abstract][Full Text] [Related]
5. Serum tissue polypeptide specific antigen as a noninvasive prognostic indicator for early recurrence of hepatocellular carcinoma after curative resection.
Yao WJ; Wang ST; Chow NH; Chang TT; Lin PW; Tu DG
Cancer; 2002 Jul; 95(1):112-8. PubMed ID: 12115324
[TBL] [Abstract][Full Text] [Related]
6. A prospective study of tissue polypeptide specific antigen (TPS) in breast cancer diagnosis.
Eskelinen M; Hippeläinen M; Salmela E; Paajanen H; Alhava E; Syrjänen K
Anticancer Res; 1992; 12(6B):2033-6. PubMed ID: 1295446
[TBL] [Abstract][Full Text] [Related]
7. [Clinical study of serum tissue polypeptide-specific antigen in breast cancer].
Zheng H; He BF; Luo RC; You CX; Mai GF; Lu HF
Di Yi Jun Yi Da Xue Xue Bao; 2003 Aug; 23(8):823-5. PubMed ID: 12919909
[TBL] [Abstract][Full Text] [Related]
8. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
[TBL] [Abstract][Full Text] [Related]
9. Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS.
Pujol JL; Grenier J; Parrat E; Lehmann M; Lafontaine T; Quantin X; Michel FB
Am J Respir Crit Care Med; 1996 Sep; 154(3 Pt 1):725-33. PubMed ID: 8810612
[TBL] [Abstract][Full Text] [Related]
10. The preoperative plasma fibrinogen level is an independent prognostic factor for overall survival of breast cancer patients who underwent surgical treatment.
Wen J; Yang Y; Ye F; Huang X; Li S; Wang Q; Xie X
Breast; 2015 Dec; 24(6):745-50. PubMed ID: 26482138
[TBL] [Abstract][Full Text] [Related]
11. Elevated preoperative serum ICTP is a prognostic factor for overall and disease-free survival in breast cancer.
Keskikuru R; Bloigu R; Risteli J; Kataja V; Jukkola A
Oncol Rep; 2002; 9(6):1323-7. PubMed ID: 12375042
[TBL] [Abstract][Full Text] [Related]
12. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
[TBL] [Abstract][Full Text] [Related]
13. Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast.
Imoto S; Wada N; Hasebe T; Ochiai A; Kitoh T
Int J Cancer; 2007 Jan; 120(2):357-61. PubMed ID: 17044019
[TBL] [Abstract][Full Text] [Related]
14. Notable relationship between the level of tumor marker TPS in serum and survival in breast cancer.
Bremer K; Eklund G; Björklund B
Anticancer Res; 1996; 16(2):905-9. PubMed ID: 8687149
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
[TBL] [Abstract][Full Text] [Related]
16. Preoperative serum visfatin levels and prognosis of breast cancer among Chinese women.
Li XY; Tang SH; Zhou XC; Ye YH; Xu XQ; Li RZ
Peptides; 2014 Jan; 51():86-90. PubMed ID: 24269296
[TBL] [Abstract][Full Text] [Related]
17. Preoperative serum levels of matrix metalloproteinase-2 (MMP-2) and survival of breast cancer among Korean women.
Song N; Sung H; Choi JY; Han S; Jeon S; Song M; Lee Y; Park C; Park SK; Lee KM; Yoo KY; Noh DY; Ahn SH; Lee SA; Kang D
Cancer Epidemiol Biomarkers Prev; 2012 Aug; 21(8):1371-80. PubMed ID: 22634108
[TBL] [Abstract][Full Text] [Related]
18. Comparison of TPS with CEA and CA 15.3 in follow-up of Chinese breast cancer patients.
Hu XC; Day W; Jones B; Loo WT; Chow LW
Anticancer Res; 2002; 22(3):1865-8. PubMed ID: 12168883
[TBL] [Abstract][Full Text] [Related]
19. The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients.
Barak V; Meirovitz A; Leibovici V; Rachmut J; Peretz T; Eliashar R; Gross M
Anticancer Res; 2015 Oct; 35(10):5519-24. PubMed ID: 26408719
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]